Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSE:EBS NASDAQ:FGEN NASDAQ:GBT NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$18.86-0.1%$15.79$9.57▼$30.41$2.61B0.931.56 million shs1.79 million shsEBSEmergent Biosolutions$7.33$6.35$4.02▼$15.10$397.86M2.091.70 million shs927,860 shsFGENFibroGen$7.35+18.7%$6.99$4.50▼$38.25$25.02M0.7475,812 shs227,026 shsGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsPTCTPTC Therapeutics$49.52+1.6%$48.11$29.02▼$58.38$3.86B0.5868,697 shs913,854 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-0.11%+12.40%+11.14%+59.97%-29.68%EBSEmergent Biosolutions+0.83%+4.86%+8.83%+67.70%-21.10%FGENFibroGen+18.74%+29.17%-4.92%+6.06%-67.46%GBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%PTCTPTC Therapeutics+1.60%+1.54%-4.29%+15.22%+55.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.7496 of 5 stars3.42.00.03.41.82.50.0EBSEmergent Biosolutions4.3941 of 5 stars3.51.00.04.62.72.51.3FGENFibroGen4.6425 of 5 stars3.33.00.04.73.83.30.6GBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APTCTPTC Therapeutics4.3258 of 5 stars4.31.00.04.41.50.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.75Moderate Buy$43.71131.78% UpsideEBSEmergent Biosolutions 3.00Buy$14.3395.54% UpsideFGENFibroGen 2.50Moderate Buy$250.003,301.36% UpsideGBTGlobal Blood Therapeutics 0.00N/AN/AN/APTCTPTC Therapeutics 2.67Moderate Buy$65.0031.26% UpsideCurrent Analyst Ratings BreakdownLatest ARWR, EBS, GBT, PTCT, and FGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025ARWRArrowhead PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.005/13/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$250.00 ➝ $250.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$545.21M4.78N/AN/A$1.54 per share12.25EBSEmergent Biosolutions$930.30M0.43$1.92 per share3.82$8.91 per share0.82FGENFibroGen$29.62M1.00N/AN/A($50.89) per share-0.14GBTGlobal Blood Therapeutics$194.75M23.73N/AN/A$3.05 per share22.46PTCTPTC Therapeutics$806.78M4.86N/AN/A($14.24) per share-3.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/A22.21N/A-45.33%-12.49%8/6/2025 (Estimated)EBSEmergent Biosolutions-$190.60M-$2.71N/A3.54N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)FGENFibroGen-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)GBTGlobal Blood Therapeutics-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/APTCTPTC Therapeutics-$363.30M$6.517.61N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)Latest ARWR, EBS, GBT, PTCT, and FGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025EBSEmergent Biosolutions$0.21N/AN/AN/A$148.55 millionN/A8/5/2025Q2 2025FGENFibroGen-$0.09N/AN/AN/A$2.88 millionN/A5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/12/2025Q1 2025FGENFibroGen$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million5/7/2025Q1 2025EBSEmergent Biosolutions$0.49$0.71+$0.22$1.19$218.50 million$222.20 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AGBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.315.155.15EBSEmergent Biosolutions1.206.323.51FGENFibroGenN/A2.021.98GBTGlobal Blood Therapeutics4.926.886.17PTCTPTC TherapeuticsN/A3.893.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%EBSEmergent Biosolutions78.40%FGENFibroGen72.71%GBTGlobal Blood TherapeuticsN/APTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%EBSEmergent Biosolutions1.20%FGENFibroGen3.07%GBTGlobal Blood Therapeutics4.90%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.10 million132.16 millionOptionableEBSEmergent Biosolutions2,42054.28 million53.63 millionOptionableFGENFibroGen5704.04 million3.92 millionOptionableGBTGlobal Blood Therapeutics45767.48 million64.17 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableARWR, EBS, GBT, PTCT, and FGEN HeadlinesRecent News About These CompaniesBanque Pictet & Cie SA Invests $342,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT)4 hours ago | marketbeat.comAllspring Global Investments Holdings LLC Makes New $524,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)July 11 at 3:29 AM | marketbeat.comPTCT - PTC Therapeutics Inc Ownership - MorningstarJuly 8 at 10:29 PM | morningstar.comMWealth Enhancement Advisory Services LLC Acquires New Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT)July 5, 2025 | marketbeat.comPTCT | PTC Therapeutics Inc. Annual Cash Flow Statement - MarketWatchJuly 4, 2025 | marketwatch.comCantor Fitzgerald Has Weak Estimate for PTCT FY2026 EarningsJuly 4, 2025 | americanbankingnews.comFY2025 EPS Estimates for PTCT Decreased by Cantor FitzgeraldJuly 3, 2025 | americanbankingnews.comFY2026 EPS Estimates for PTCT Cut by Cantor FitzgeraldJuly 2, 2025 | marketbeat.comCantor Fitzgerald Has Weak Estimate for PTCT FY2025 EarningsJuly 1, 2025 | marketbeat.comPTC Therapeutics Inc. (PTCT) Stock Price Today - WSJJune 30, 2025 | wsj.comPTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS RatingJune 30, 2025 | msn.comPTC Therapeutics Gets Marketing Authorization For Sephience In EU To Treat Phenylketonuria - NasdaqJune 24, 2025 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Perspective Therapeutics (CATX) and PTC Therapeutics (PTCT)June 24, 2025 | theglobeandmail.comPTC Therapeutics Inc News (PTCT) - Investing.comJune 24, 2025 | investing.comPTC Therapeutics’ Sephience gets European marketing authorization to treat children and adults living with phenylketonuriaJune 24, 2025 | pharmabiz.comPPTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJune 24, 2025 | prnewswire.comSephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)June 23, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 22, 2025 | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 22, 2025 | marketbeat.comTruist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug LaunchesJune 20, 2025 | msn.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 19, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARWR, EBS, GBT, PTCT, and FGEN Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$18.86 -0.02 (-0.11%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$18.84 -0.02 (-0.11%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Emergent Biosolutions NYSE:EBS$7.33 0.00 (0.00%) Closing price 07/10/2025 03:59 PM EasternExtended Trading$7.39 +0.06 (+0.83%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.FibroGen NASDAQ:FGEN$7.35 +1.16 (+18.74%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$7.40 +0.04 (+0.61%) As of 09:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Global Blood Therapeutics NASDAQ:GBTGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.PTC Therapeutics NASDAQ:PTCT$49.52 +0.78 (+1.60%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$49.25 -0.27 (-0.55%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.